🇺🇸 BDP in United States

FDA authorised BDP on 12 May 1976 · 10 US adverse-event reports

Marketing authorisations

FDA — authorised 12 May 1976

  • Application: NDA017573
  • Marketing authorisation holder: SCHERING
  • Local brand name: VANCERIL
  • Indication: AEROSOL, METERED — INHALATION
  • Status: approved

Read official source →

FDA — authorised 15 September 2000

  • Application: NDA020911
  • Marketing authorisation holder: TEVA BRANDED PHARM
  • Local brand name: QVAR 40
  • Indication: AEROSOL, METERED — INHALATION
  • Status: approved

Read official source →

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Activities Of Daily Living Impaired — 1 report (10%)
  2. Asthma — 1 report (10%)
  3. Body Temperature Decreased — 1 report (10%)
  4. Central Obesity — 1 report (10%)
  5. Cushing^S Syndrome — 1 report (10%)
  6. Decreased Appetite — 1 report (10%)
  7. Disseminated Cryptococcosis — 1 report (10%)
  8. Disseminated Intravascular Coagulation — 1 report (10%)
  9. Drug Interaction — 1 report (10%)
  10. Dry Mouth — 1 report (10%)

Source database →

Other Respiratory / Pulmonology approved in United States

Frequently asked questions

Is BDP approved in United States?

Yes. FDA authorised it on 12 May 1976; FDA authorised it on 15 September 2000.

Who is the marketing authorisation holder for BDP in United States?

SCHERING holds the US marketing authorisation.